MRTNZ Investment Office · S&P 500 · The 360 Vantage
ABBV · NYSE
AbbVie Inc.
Health Care · Biotechnology: Pharmaceutical Preparations
Reference price$258.50As of Jul 30, 2026
Street view
Analyst targets
Published sell-side aggregation—not an MRTNZ forecast.
Forward calendar
Current earnings expectations
Consensus may change until the company reports.
Dec 2026$14.14Street EPS consensus
Dec 2027$16.20Street EPS consensus
Dec 2028$17.80Street EPS consensus
Reported results
Annual financial snapshot
Fiscal period ended Dec 31, 2025.
MetricCurrentPrior
Revenue+8.6% YoY$61.16B$56.33B
Operating income$15.08B$9.14B
Net income$4.23B$4.28B
Operating cash flow$19.03B$18.81B
Capital expenditures($1.21B)($0.97B)
Current context
Related news
Company-linked articles surfaced by Nasdaq.
The Motley Fool
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
→The Motley FoolAbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?
→RTTNewsAbbVie Wins EC Approval For Rinvoq In Non-Segmental Vitiligo
→Evidence
Sources & method
Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →
Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.